NIH Will Not “March-In” On Pfizer’s Xalatan
Similar to its decision in the Norvir case, NIH says availability, not price, is test of whether the agency can “march-in” on a company’s exclusivity.
Similar to its decision in the Norvir case, NIH says availability, not price, is test of whether the agency can “march-in” on a company’s exclusivity.